Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan

Table 3 Base-case results

Strategy	Cost JPY (USD)	Incrmental Cost JPY (USD)	QALY	Incremental QALY	ICER JPY/QALY (USD/QALY)
PALO regimen	30,348 (270.55)	10,455 (93.21)	0.009598	0.000645208	16,204,591 (144,465)
GRA regimen	19,893 (177.35)		0.008952

JPY Japanese yen, QALY Quality-adjusted life year, ICER Incremental cost-effectiveness ratio. Exchange rate, 1 USD = 112.17 JPY

ISSN: 1472-6963